Literature DB >> 19351941

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.

Christopher M O'Connor1, David J Whellan, Kerry L Lee, Steven J Keteyian, Lawton S Cooper, Stephen J Ellis, Eric S Leifer, William E Kraus, Dalane W Kitzman, James A Blumenthal, David S Rendall, Nancy Houston Miller, Jerome L Fleg, Kevin A Schulman, Robert S McKelvie, Faiez Zannad, Ileana L Piña.   

Abstract

CONTEXT: Guidelines recommend that exercise training be considered for medically stable outpatients with heart failure. Previous studies have not had adequate statistical power to measure the effects of exercise training on clinical outcomes.
OBJECTIVE: To test the efficacy and safety of exercise training among patients with heart failure. DESIGN, SETTING, AND PATIENTS: Multicenter, randomized controlled trial of 2331 medically stable outpatients with heart failure and reduced ejection fraction. Participants in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) were randomized from April 2003 through February 2007 at 82 centers within the United States, Canada, and France; median follow-up was 30 months.
INTERVENTIONS: Usual care plus aerobic exercise training, consisting of 36 supervised sessions followed by home-based training, or usual care alone. MAIN OUTCOME MEASURES: Composite primary end point of all-cause mortality or hospitalization and prespecified secondary end points of all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or heart failure hospitalization.
RESULTS: The median age was 59 years, 28% were women, and 37% had New York Heart Association class III or IV symptoms. Heart failure etiology was ischemic in 51%, and median left ventricular ejection fraction was 25%. Exercise adherence decreased from a median of 95 minutes per week during months 4 through 6 of follow-up to 74 minutes per week during months 10 through 12. A total of 759 patients (65%) in the exercise training group died or were hospitalized compared with 796 patients (68%) in the usual care group (hazard ratio [HR], 0.93 [95% confidence interval {CI}, 0.84-1.02]; P = .13). There were nonsignificant reductions in the exercise training group for mortality (189 patients [16%] in the exercise training group vs 198 patients [17%] in the usual care group; HR, 0.96 [95% CI, 0.79-1.17]; P = .70), cardiovascular mortality or cardiovascular hospitalization (632 [55%] in the exercise training group vs 677 [58%] in the usual care group; HR, 0.92 [95% CI, 0.83-1.03]; P = .14), and cardiovascular mortality or heart failure hospitalization (344 [30%] in the exercise training group vs 393 [34%] in the usual care group; HR, 0.87 [95% CI, 0.75-1.00]; P = .06). In prespecified supplementary analyses adjusting for highly prognostic baseline characteristics, the HRs were 0.89 (95% CI, 0.81-0.99; P = .03) for all-cause mortality or hospitalization, 0.91 (95% CI, 0.82-1.01; P = .09) for cardiovascular mortality or cardiovascular hospitalization, and 0.85 (95% CI, 0.74-0.99; P = .03) for cardiovascular mortality or heart failure hospitalization. Other adverse events were similar between the groups.
CONCLUSIONS: In the protocol-specified primary analysis, exercise training resulted in nonsignificant reductions in the primary end point of all-cause mortality or hospitalization and in key secondary clinical end points. After adjustment for highly prognostic predictors of the primary end point, exercise training was associated with modest significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or heart failure hospitalization. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00047437.

Entities:  

Mesh:

Year:  2009        PMID: 19351941      PMCID: PMC2916661          DOI: 10.1001/jama.2009.454

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  23 in total

1.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

2.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Authors:  J N Cohn; G Tognoni
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

4.  Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH).

Authors:  M F Piepoli; C Davos; D P Francis; A J S Coats
Journal:  BMJ       Date:  2004-01-16

5.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems.

Authors:  Stuart J Pocock; Susan E Assmann; Laura E Enos; Linda E Kasten
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

Review 6.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

7.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

Review 8.  Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity.

Authors:  Neil Smart; Thomas H Marwick
Journal:  Am J Med       Date:  2004-05-15       Impact factor: 4.965

9.  Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing).

Authors:  Daniel R Bensimhon; Eric S Leifer; Stephen J Ellis; Jerome L Fleg; Steven J Keteyian; Ileana L Piña; Dalane W Kitzman; Robert S McKelvie; William E Kraus; Daniel E Forman; Andrew J Kao; David J Whellan; Christopher M O'Connor; Stuart D Russell
Journal:  Am J Cardiol       Date:  2008-07-09       Impact factor: 2.778

10.  A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1983-10       Impact factor: 24.094

View more
  541 in total

1.  [Aerobic and strength training in patients with diabetes mellitus type 2 and heart failure].

Authors:  D Niederseer; J Niebauer
Journal:  Herz       Date:  2012-08       Impact factor: 1.443

Review 2.  Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials.

Authors:  Ambarish Pandey; Akhil Parashar; Dharam Kumbhani; Sunil Agarwal; Jalaj Garg; Dalane Kitzman; Benjamin Levine; Mark Drazner; Jarett Berry
Journal:  Circ Heart Fail       Date:  2014-11-16       Impact factor: 8.790

Review 3.  Clinical utility of exercise training in chronic systolic heart failure.

Authors:  Andrew J Stewart Coats
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

4.  Tai chi exercise in patients with chronic heart failure: a randomized clinical trial.

Authors:  Gloria Y Yeh; Ellen P McCarthy; Peter M Wayne; Lynne W Stevenson; Malissa J Wood; Daniel Forman; Roger B Davis; Russell S Phillips
Journal:  Arch Intern Med       Date:  2011-04-25

5.  Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale.

Authors:  Gordon R Reeves; David J Whellan; Pamela Duncan; Christopher M O'Connor; Amy M Pastva; Joel D Eggebeen; Leigh Ann Hewston; Timothy M Morgan; Shelby D Reed; W Jack Rejeski; Robert J Mentz; Paul B Rosenberg; Dalane W Kitzman
Journal:  Am Heart J       Date:  2016-12-28       Impact factor: 4.749

Review 6.  Cardiac rehabilitation past, present and future: an overview.

Authors:  Warner M Mampuya
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

Review 7.  The potential role of endogenous bacteriophages in controlling invading pathogens.

Authors:  Andrzej Górski; Beata Weber-Dabrowska
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

8.  Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Authors:  Andrew P Ambrosy; Ankeet S Bhatt; Amanda L Stebbins; Lisa M Wruck; Marat Fudim; Stephen J Greene; William E Kraus; Christopher M O'Connor; Ileana L Piña; David J Whellan; Robert J Mentz
Journal:  Am Heart J       Date:  2018-02-11       Impact factor: 4.749

Review 9.  Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure.

Authors:  An M Van Berendoncks; Anne Garnier; Renée Ventura-Clapier; Viviane M Conraads
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 10.  [Chronic heart failure and depression].

Authors:  C Herrmann-Lingen
Journal:  Internist (Berl)       Date:  2018-05       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.